Michael Morelli on Retatrutide: Fact Check

The central evidence distinction is clear: retatrutide has demonstrated weight and glucose effects in trials, but those results do not establish that it builds muscle, improves cognition or validates a vendor’s product.

The Triple Agonist Mechanism

The earlier review recorded a description of retatrutide as a triple agonist. That description of the molecule is correct: it activates GLP-1, GIP and glucagon receptors.

"This Stuff Is Anabolic" — Muscle Preservation Claims

The anabolic claim recorded in the earlier review is not established by clinical evidence. The Phase 2 DXA substudy in adults with type 2 diabetes found reductions in both fat and lean mass over 36 weeks. It did not establish retatrutide as a muscle-building treatment.

The previous article’s estimate that 75–80% of weight loss was fat, and its claim that retatrutide preserves muscle better than semaglutide, were not supported by the retrieved primary source. The substudy compared retatrutide with placebo and dulaglutide, not semaglutide or tirzepatide.

DXA lean mass is also not identical to skeletal muscle: it includes other nonfat soft tissue. Neither a group-average decrease nor an individual report of gaining strength proves what caused a particular person’s result.

Cognitive Clarity and "Flow State" Claims

The earlier review recorded claims about mental clarity, brain fog and a “flow state.” The retrieved retatrutide weight-loss and diabetes trials do not establish those effects or demonstrate a change in human dopamine levels.

A personal experience cannot establish a drug effect without a suitable comparison. It would also be unsupported to diagnose that experience as a placebo response, improved sleep or better glucose stability. The cause remains unverified.

Retatrutide "Increases Energy Expenditure"

The preclinical work supports an energy-expenditure mechanism in mice. The prior review incorrectly treated this as a measured, statistically significant human Phase 2 result.

Human weight loss does not by itself show whether energy expenditure rose, how much it changed or how that compares with other drugs. Receptor biology is a research rationale, not proof that retatrutide prevents metabolic adaptation.

"Rapid Fat Loss Without Muscle Loss" and Non-Standard Dosing

The earlier article recorded claims about losing fat without losing muscle and using a different dosing approach. The DXA substudy does not establish a no-lean-loss guarantee. Nor do the cited trials validate an unnamed alternative regimen.

Trial dosing schedules describe investigational research. They are not an approved prescription or a way to establish the identity, strength or suitability of an online product. A claim that clients became stronger while losing weight also cannot isolate a drug effect from training, diet or other interventions.

Grey Market Peptide Sources

The prior review recorded a claim that a research-peptide supplier provided the same products as pharmacies. That supplier claim was not independently verified in this review.

FDA states that retatrutide is not a component of an approved drug and cannot be used in compounding under federal law. A “research use only” label does not authorize human treatment. A certificate about a sample also does not establish that the product a buyer receives is an approved or appropriate medicine.

Frequently Asked Questions

Sources

• Original video linked by the earlier review; unavailable during this update: YouTube source.
• Coskun, T., et al. (2022). Preclinical and early clinical characterization of LY3437943. Cell Metabolism
• FDA. Current concerns about unapproved GLP-1 drugs. FDA
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Coskun, T., et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial. The Lancet Diabetes & Endocrinology, 13(8), 674-684. DOI: 10.1016/S2213-8587(25)00092-0
• Eli Lilly and Company. (2025). TRIUMPH-4 topline results: Retatrutide achieved significant weight loss and improved knee osteoarthritis pain. Press release
• FDA. (2023-2025). Warning letters to compounding pharmacies and research peptide vendors regarding GLP-1 receptor agonist products. FDA.gov